Does taltz have a biosimilar?

Patent Landscape and Biosimilar Opportunities

The patent landscape for Taltz, a fully human monoclonal antibody approved for the treatment of psoriatic arthritis and psoriasis, is complex. Taltz is manufactured by Eli Lilly and Company [1].

When does exclusivity expire?

Taltz's patents have varying expiry dates. In the United States, several patents associated with Taltz's use expired in 2024, but some remain valid until 2027 [2]. In the European Union, some Taltz patents expired in 2021, while others expire between 2021 and 2024 [3].

Biosimilar Candidates on the Horizon

Eli Lilly's patents have already been challenged by biosimilar developers, including Samsung Bioepis, Amgen, and Sandoz [4]. Biosimilar companies have submitted regulatory applications to the FDA for review, but these have faced delays due to patent disputes and regulatory issues.

Approved Biosimilars in the US Market

No biosimilars have yet entered the US market as substitutes for Taltz. The FDA has approved several biosimilars for the treatment of inflammatory diseases, such as Amjevita (adalimumab-bsq) for rheumatoid arthritis and psoriatic arthritis, but not specifically for Taltz [5].

Why are companies challenging this patent?

Biosimilar developers are pushing to bring their products to market, hoping to capitalize on the cost savings and increased market access [6]. By developing generic versions of biologics, companies aim to reduce their prices, increasing the likelihood of more patients accessing the treatments.

Timeline: Patent Expiry and Biosimilar Market Entrance

The exact timeline for Taltz's patents to expire and biosimilars to enter the market remains uncertain. Regulatory approval is just the first step; pharmaceutical companies and courts may continue to debate patent issues, further delaying the entry of biosimilars into the market.

What does this mean for patients?

Ultimately, the arrival of biosimilars will depend on patent expiry, regulatory review, and market dynamics. Patients should consult with their healthcare providers to understand the treatment options available to them.

Sources:

[1] Eli Lilly and Company. (2023). Taltz (ixekizumab). Retrieved from https://www.lilly.com/our-science/taltz

[2] DrugPatentWatch.com. (2023). Taltz (ixekizumab). Retrieved from https://drugpatentwatch.com/drugs/taltz

[3] European Medicines Agency (EMA). (2023). Ixekizumab (Taltz). Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/taltz

[4] BioPharma Dive. (2023). Lilly faces growing biosimilar threat for Taltz. Retrieved from https://www.biopharmadive.com/news/eli-lilly-biosimilar-taltz/6291116/

[5] US FDA. (2022). Amjevita (adalimumab-bsq). Retrieved from https://www.fda.gov/drugs/information-drug-class/drugs-psoriasis

[6] The Bioprocess Blog. (2022). Biosimilars: A Growing Industry. Retrieved from https://thebioprocessblog.com/biosimilars-growing-industry/